This article was originally published in The Tan Sheet
Bayer will submit a citizen petition requesting that FDA reopen the cough/cold nasal decongestants monograph to include PEB, firm says. Company is looking to use the ingredient in Alka-Seltzer Plus effervescent formulations. During a Feb. 15 "feedback" meeting, FDA representatives suggested Bayer either submit a petition to reopen the monograph or file Section 505(b)(2) NDAs for each formulation (1"The Tan Sheet" Feb. 18, 2002, p. 4)...
You may also be interested in...
Bayer should supply foreign marketing data for phenylephrine bitartrate (PEB) to support its request the ingredient be approved for use as a nasal decongestant, FDA said at a "feedback" meeting in Rockville, Md. Feb. 15
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.